Wells Fargo raised the firm’s price target on Acelyrin (SLRN) to $13 from $11 and keeps an Equal Weight rating on the shares. The firm is adjusting its model with a higher probability of success, POS, for lonigutamab rising to 50% from 30% based on the drug’s Phase 1/2 TED data, as it suggests it is active and looks similar to Xeris’ (XERS) Tepezza, but as a low volume subcutaneous dose, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SLRN:
- ACELYRIN Reports Promising Trials for Thyroid Eye Disease Drug
- Acelyrin Inc options imply 7.3% move in share price post-earnings
- Acelyrin says Phase 2b/3 trial of izokibep met primary endpoint
- ACELYRIN Reports Positive Izokibep Trial Results, Transitions Services
- ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit – Improving Quality of Life for Patients
